🐦 推特Adam Feuerstein (STAT)Codex · 实盘不做把握 5/10
北京时间·🕒 发布 20:13:44时区推断·⟳ 抓取 20:14:11·⚡ 决策 08-14 20:16:26 +2m15s·73.8 天前
STAT记者质疑Capricor关于deramiocel获FDA宽容的说法
这条信号本身是知名生物科技记者的负面解读，不是FDA新文件或公司正式披露，因此不能单独构成强空新催化。
📄 原文Adam Feuerstein (STAT)@adamfeuerstein↗ 原文
RE: $CAPR - to reiterate what I said last night: It's rather ridiculous to take seriously CEO Linda Marban's sparse com…
不做 Capricor Therapeutics（CAPR.US）
负面方向成立但本条只是记者对CEO表态的盘前评论，核心监管利空已在7月底公开传播，且缺少可用实时报价，不能按契约给SHORT_ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 报道FDA顾问委员会以9比3认为deramiocel有效性证据不足，构成本轮监管负面背景。
- 进一步传播顾问委员会负面投票，并提示FDA最终决定日期为2026-08-22。
- Adam Feuerstein质疑CEO关于FDA可能接受24个月OLE PUL数据的说法，属于记者负面判断而非监管新增事实。
关键理由
- 这条信号本身是知名生物科技记者的负面解读，不是FDA新文件或公司正式披露，因此不能单独构成强空新催化。
- 已有公开资料显示FDA顾问委员会此前以9比3认为deramiocel现有证据不支持DMD心肌病有效性，监管风险确实仍高。
- Capricor 10-Q披露公司尚无获批商业产品，deramiocel审批成败对公司收入基线和估值叙事高度关键。
主要风险
- 若FDA在2026-08-22前后仍选择批准或给出可补充路径，当前负面解读会迅速失效。
- 无法取得可用实时报价，按契约不能给CAPR.US做空ENTER。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-03-10 · 影响 weakens
公司称FDA已恢复BLA审评并设定2026-08-22 PDUFA，且公司仍强调HOPE-3数据支持潜在获批。
检索:Capricor deramiocel BLA PDUFA FDA positive HOPE-3 OLE approval counter evidence 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-05-12 · 影响 weakens
公司一季度更新称审评仍在进行、预计标签讨论开始且现金可支持至2027年四季度，说明尚非确定失败事件。
检索:Capricor Q1 2026 deramiocel labeling discussions cash PRV counter evidence 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足与报价缺失共同压低置信度，最终不输出做空ENTER。
方向:未形成可用于定价的同市场高相似先例；方向主要由FDA顾问委员会负面投票和记者质疑共同指向监管风险上升。
涨幅量级:缺少event_study与实时行情，不能量化短线下跌幅度。
形态:生物科技PDUFA前负面监管评论可能引发波动，但本条不是监管新文件，见光死或反向修复风险都较高。
原文全文
展开原文 · 986 字
RE: $CAPR - to reiterate what I said last night: It's rather ridiculous to take seriously CEO Linda Marban's sparse comments about FDA leniency re the deramiocel BLA.
What we learned definitively during the recent adcomm is that Capricor (at best) mischaracterized crucial data from the HOPE-3 study. The FDA in the strongest language possible found the PUL and cardiomyopathy data insufficient and raised serious concerns about the conduct of HOPE-3. The adcomm vote was overwhelmingly negative.
So now, without any proof or substantiation, we're to believe Marban when she says the FDA is going to accept 24-month OLE data on PUL from a study it already rejected as insufficient?
This entire situation is sad. Duchenne patients are caught in the middle, but Capricor has damaged its own credibility. Her comments last night sound like a desperate attempt to avoid having to conduct another clinical trial, which clearly should be done if deramiocel is ever going to be approved.
What we learned definitively during the recent adcomm is that Capricor (at best) mischaracterized crucial data from the HOPE-3 study. The FDA in the strongest language possible found the PUL and cardiomyopathy data insufficient and raised serious concerns about the conduct of HOPE-3. The adcomm vote was overwhelmingly negative.
So now, without any proof or substantiation, we're to believe Marban when she says the FDA is going to accept 24-month OLE data on PUL from a study it already rejected as insufficient?
This entire situation is sad. Duchenne patients are caught in the middle, but Capricor has damaged its own credibility. Her comments last night sound like a desperate attempt to avoid having to conduct another clinical trial, which clearly should be done if deramiocel is ever going to be approved.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。